Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054636 · ClinicalTrials.gov registry record
Short-term Perfusion Angiography Pilot Study (SPA)
A clinical trial, sponsored by Volcano Corporation.
- Terminated
- Registry status
- 38
- Enrollment target
NCT03054636: Clinical Trial study, sponsored by Volcano Corporation.
NCT03054636 is a clinical trial that was terminated before completion, run by Volcano Corporation. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054636 was terminated before completion, sponsored by Volcano Corporation.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The Short term Perfusion Angiography (SPA) study is designed to collect 2D Perfusion data from Critical Limb Ischemia (CLI) endovascular (interventional) procedures for information on device performance in a real-world setting.
Primary Outcome
Freedom from Major Adverse Device Effects through 30 day visit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-02-14 |
Why NCT03054636 stopped before completion
NCT03054636 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03054636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03054636 about?
NCT03054636 is a clinical study titled "Short-term Perfusion Angiography Pilot Study (SPA)". The Short term Perfusion Angiography (SPA) study is designed to collect 2D Perfusion data from Critical Limb Ischemia (CLI) endovascular (interventional) procedures for information on device performance in a real-world setting.
What is the current status of trial NCT03054636?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2017-01. Estimated completion is 2019-02-14.
Who is sponsoring clinical trial NCT03054636?
This trial is sponsored by Volcano Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia